ARIH1 and neoplasm: To test whether ARIH1 is required for the anti-tumor effects of cisplatin-enhanced PD-L1 blockade therapy, we tested the therapeutic efficacy against a subcutaneously tumor model established with Arih1-knockdown 4T1 cells.